Polypharmacy among people living with type 2 diabetes mellitus in rural communes in Vietnam

Dieu Huyen Thi Bui1*, Bai Xuan Nguyen2, Dat Cong Truong1, Dan Wolf Meyrowitsch3, Jens Søndergaard4, Tine Gammeltoft5, Ib Christian Bygbjerg3, Nielsen Jannie3,6

1 Faculty of Public Health, Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam,
2 Department of Embryology, Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam,
3 Department of Public Health, Global Health Section, University of Copenhagen, Copenhagen K, Denmark,
4 Department of Public Health, The Research Unit for General Practice, University of Southern Denmark, Odense C, Denmark,
5 Department of Anthropology, University of Copenhagen, Copenhagen K, Denmark,
6 Hubert Department of Global Health, Emory Global Diabetes Research Center, Rollins School of Global Health, Emory University, Atlanta, GA, United States of America

* huyendieu1410@gmail.com

Abstract

Objectives

People with diabetes are at high risk of polypharmacy owing to complex treatment of diabetes and comorbidities. Polypharmacy is associated with increased risk of adverse reactions and decreased compliance. Therefore, the objectives of this study were to assess polypharmacy in people with type 2 diabetes (T2D) and associated diabetes-related factors in rural areas in Vietnam.

Method

People with T2D (n = 806) who had received treatment for diabetes at a district hospital were invited to participate in a questionnaire-based cross-sectional survey. Polypharmacy was defined as ≥5 types of medicine and assessed as a) prescription medicine and non-prescription/over the counter (OTC) medicine and b) prescription medicine and non-prescription/OTC, herbal and traditional medicine, and dietary supplement. Multiple logistic regression was used to investigate the association between polypharmacy and diabetes specific factors: duration, comorbidities and diabetes-related distress.

Results

Of the people with T2D, 7.8% had a medicine use corresponding to polypharmacy (prescription medicine and supplements), and 40.8% when herbal and traditional medicine, and dietary supplement were included. Mean number of medicine intake (all types of medicines and supplements) were 3.8±1.5. The odd ratios (ORs) of polypharmacy (medicine and supplements) increased with diabetes duration (<1–5 years OR = 1.66; 95%CI: 1.09–2.53 and >5 years OR = 1.74; 95%CI: 1.14–2.64 as compared to ≤1-year duration of diabetes), number of comorbidities (1–2 comorbidities: OR = 2.0; 95%CI: 1.18–3.42; ≥3

* huyendieu1410@gmail.com
comorbidities: OR = 2.63; 95% CI: 1.50–4.61 as compared to no comorbidities), and suffering from diabetes-related distress (OR = 1.49; 95% CI: 1.11–2.01) as compared to those without distress.

Conclusions

In rural northern Vietnam, persons with longer duration of T2D, higher number of comorbidities and diabetes-related stress have higher odds of having a medicine use corresponding to polypharmacy. A high proportion of people with T2D supplement their prescription, non-prescription/OTC medicine with herbal and traditional medicine and dietary supplements.

Introduction

The prevalence of diabetes among adults in Vietnam has increased from 2.7% in 2002 [1] to 6% in 2017 [2]. To prevent complications and comorbidities such as hypertension, heart disease and arthritis [2,3], people with diabetes must daily adhere to glucose-lowering medicine, monitor and test their blood glucose, address cardiovascular disease risk factors, including blood pressure [4] and lipid management [5,6], and often significantly change their diet and physical activity level [7]. Consequently, people living with diabetes often have to use multiple medicines for their diabetes, comorbidities and complications [8]. Concomitant use of multiple medicines can be harmful even when each drug is prescribed according to clinical guidelines because each additional medicine increases the risk of adverse reactions and decreased compliance [9].

The use of multiple medications is defined as “polypharmacy” [10]. There is no consensus on the definition of polypharmacy: polypharmacy has been defined both excluding [11] and including none-Western medications such as herbal and traditional medicine and dietary supplements [12]. Studies defining polypharmacy as only prescribed/OTC medicine have reported that polypharmacy is associated with adverse drug events, drug-drug interaction, hospitalization, cost [13], mortality, and morbidity [14]. Previous studies also showed that people with diabetes more often have medication use corresponding to polypharmacy than people without diabetes [11,15]. Further, polypharmacy reduces adherence to the medicine and decreases the quality of life in people with diabetes [14].

The majority of studies on polypharmacy in people with diabetes have been conducted in high-income countries, and very few have focused on middle-income countries such as Vietnam. A study from Vietnam showed that the rate of polypharmacy among hospitalized patients in general aged 60 years and older was 59.2% [16]. The proportion of people with diabetes with polypharmacy is not known. Therefore, a cross-sectional study was conducted to assess the proportion of adult Vietnamese age ≥40 year with type 2 diabetes (T2D) who have a medicine intake corresponding to polypharmacy and identify factors associated with polypharmacy.

Materials and methods

Study population and setting

A cross-sectional survey was conducted from December 2018 to February 2019 in Thai Binh Province, a province in North-eastern Vietnam. The total population is 1.86 million people, GDP per capita 1.650 USD, and more than 90% of the population live in rural areas [17]. Thai
Binh Province is subdivided into seven districts and one provincial city and has a total of 9
townlets, 10 wards, and 267 communes.

The state health care system in Vietnam is organized as a four-tiered pyramid. At the top of
the pyramid is the Ministry of Health, which subsumes provincial, district and commune
health authorities. Thai Binh Province has 12 district hospitals and 2 private hospitals, which
are equivalent to district hospitals. People with diabetes can receive treatment at any of these
hospitals and they can change the hospital anytime they want.

**Sampling method**

Among the seven districts of Thai Binh Province, we selected two districts, Quynh Phu District
in the north and Vu Thu District in the south. In each district, the two communes with the
highest number of people with T2D were selected. Of these communes, we selected two neigh-
boring communes as these were convenient for data collection. Thus, out of 68 towns/comm-
unes in two districts, 8 were selected.

People with T2D residing in the 8 selected communes who had received treatment for their
diabetes at the 3 district hospitals in Quynh Phu District and Vu Thu District were invited to
take part in the study. Information on name, address, and phone number for these people were
based on hospital records and provided by the district hospitals. In Vietnam, hospitals diagnoses
diabetes using the WHO criteria. From the 8 communes, 963 people with T2D were invited to
participate in the study; 37 respondents refused to participate in the study (3.8%), while 78
respondents could not be found at the reported address or had relocated (8.1%). In Vietnam,
age of onset of T2D has been shown to be in the fourth to fifth decade of life [18], while type 1
diabetes is generally diagnosed at younger ages [2]. Our target population was people with T2D,
thus, to minimize the potential of misclassification we excluded those with diabetes diagnosed
before 40 years of age and those who did not remember their age when diagnosed (n = 42,
4.4%). These criteria resulted in a cohort of 806 people with T2D (respondence rate: 83.7%).

**Ethical approval**

The study was approved by the Medical Ethics Committee of Thai Binh University of Medi-
cine and Pharmacy, Vietnam, (decision 11/2018, 23rd November 2018). Written informed
consent was obtained from each participant before data collection. Participants could with-
draw at any time during the interview. The participants were interviewed in their homes or
another place selected by them. The completed questionnaires were managed and stored
securely at Thai Binh University of Medicine and Pharmacy, Vietnam.

**Data collection**

Data were collected using a structured and pilot-tested questionnaire. We trained 16 village
health workers from 8 health stations in the 8 selected communes as interviewers at a 2-day
workshop followed by field-based training and counseling to administer the questionnaires.
The interviews were as arranged through the staff of the commune health station. To ensure
the questions were culturally appropriate and could be understood by the study participants,
the questionnaire was pilot tested first among village health workers and second among people
admitted to the hospital for diabetes.

**Study variables**

**Outcome.** The number of medicines was reported by the person with T2D during the
interview, who was encouraged to report prescription medicines, OTC medicines they
purchased, herbal and traditional medicine, and dietary supplements, and to show all the medicines they were taking daily.

**Definition of polypharmacy.** There is no general consensus for the definition of polypharmacy, but daily intake of ≥5 medicines is the most commonly used to define polypharmacy [11,12,19]. However, the definition of what constitutes medicines varies by either excluding or including non-western medicines such as herbal and traditional medicine and dietary supplements [11,12]. In the present study, we created two variables for polypharmacy: a) one only including prescribed medicine and non-prescription/over the counter medicine (OTC); and b) a variable including prescribed medicine and non-prescription/OTC medicine, herbal and traditional medicine, and dietary supplements [12]. Polypharmacy was categorized as: no (0), yes (1). For modeling purposes, we used the second definition as herbal and traditional medicine, and dietary supplements are commonly used in Vietnam.

**Exposure.** Our main exposures of interest were variables related to the participant’s T2D: duration of diabetes, physical health, number of comorbidities, and diabetes-related distress. All this information was self-reported. Comorbidities were coded as 0, 1–2 comorbidities, 3 or more comorbidities [20]; and duration of diabetes as ≤1 year, >1–5 years, >5 years) [21]. Diabetes-related distress (no, yes) [22] was defined according to the Problem Areas in Diabetes 5 (PAID-5) scale [23].

**Covariates.** Covariates were factors known to be associated with polypharmacy and were categorized as follows: Age (categorized as 40–54 years, 55–69 years, ≥70 years) [15], sex (man, woman) [11], education (primary school and below, middle school, college and above) [24]; economic status (poor/near-poor, medium, wealthy) [25]; occupation (unemployed, farmer, small trade/worker/government employee/private company, retired), marital status (married/living together, single/widowed/divorced) [26], and self-reported physical health (excellent/good, fair, poor/very poor) [27].

**Statistical analysis**

Data were double entered using Epidata version 3.1 (The Epidata Association), cleaned and exported to SPSS (IBM Statistical Package for Social Science software) version 22 for analysis. Statistics of continuous variables were described using mean and standard deviation (SD), and categorical variables were summarized by calculating the number and frequency distribution. Bivariate logistic regression analysis was used to calculate the odd ratios (ORs) for the association between polypharmacy and independent variables and only those independent variables satisfied p-value ≤0.1. Next, multiple logistic regressions were adjusted for all independent variable satisfied p-value ≤0.1 in the bivariate logistic regressions. Adjusted odds ratios (AOR) with a 95% confidence interval (95% CI) and p-values <0.05 were used to determine if a risk factor was statistically significantly associated with polypharmacy.

**Results**

Out of 806 people living with T2D, 425 (52.7%) were women. The majority of the respondents were in the age group 55–69 years (58.1%). Mean age of the participants was 65.2±9.0 years. Mean duration of diabetes was 5.9 years. One-third (33.3%) of respondents suffered from more than three comorbidities. Half of the respondents (50.0%) presented with diabetes-related distress.

**Polypharmacy**

Mean number of medicines was 3.8 (1.5) (including prescription/OTC medicine, herbal and traditional medicine, and dietary supplements), ranging from 0 to 9 medicines per individual individual.
(distribution of prescription/OTC medicines: 1: 6.6%; 2: 15.1%; 3: 16.6%; 4: 52.7%; ≥5: 7.8%). Table 1 shows that 7.8% of participants had medicine intake corresponding to polypharmacy (using the definition including only prescribed medicine and OTC medicine), while 40.8% had polypharmacy according to the definition also including herbal and traditional medicine, and dietary supplements.

Table 2 shows the characteristics of people with T2D with and without polypharmacy (including herbal and traditional medicine and dietary supplements). Sex, marital status, occupation, education level, economic status and self-report of physical health did not differ between people with and without polypharmacy. Polypharmacy was associated with duration of diabetes, increasing number of comorbidities, and diabetes-related distress.

Factors associated with polypharmacy

The analysis of logistic regression indicated that the factors associated with polypharmacy were duration of diabetes above 1 year, presence of more than 1 comorbidity, and having diabetes-related distress (Table 3). Compared to those without comorbidities, the ORs of polypharmacy in people with 1–2 comorbidities and ≥3 comorbidities were 2.01 and 2.63 respectively. Polypharmacy was associated with duration of diabetes: compared to those who had diabetes for ≤1 year, those with diabetes for 1–5 years and >5 years had higher ORs of polypharmacy was 1.66 and 1.74, respectively. People with diabetes-related distress had higher OR of polypharmacy as compared to those without diabetes-related distress (OR = 1.49).

Discussion

This study shows that among people with T2D in rural Vietnam, 7.8% has polypharmacy when defined as ≥5 prescribed/OTC medicines, and 40.8% when also including herbal, traditional medicine and dietary supplements in the polypharmacy definition. Polypharmacy was associated with longer duration of diabetes, increasing number of comorbidities and diabetes related to distress. There was no association between polypharmacy and demographic or socio-economic factors.

Table 1. Medicine use among patients with Type 2 diabetes in Thai Binh, Vietnam.

|                                      | No n (%) | Yes n (%) |
|--------------------------------------|----------|-----------|
| Only Prescription/OTC\(^1\)          | 301 (37.3) | 505 (62.7) |
| Prescription/OTC\(^1\) + Herbal and Traditional Medicine | 3 (0.3) | 803 (99.7) |
| Prescription/OTC\(^1\) + Dietary Supplements | 6 (0.7) | 800 (99.3) |
| Prescription/OTC\(^1\) + Herbal, Traditional Medicine, Dietary Supplements | 3 (0.3) | 803 (99.7) |
| Only Herbal and Traditional Medicine | 800 (99.3) | 6 (0.7) |
| Only Herbal and Traditional Medicine and Dietary Supplements | 800 (99.3) | 6 (0.7) |
| Only Dietary Supplements             | 806 (100.0) | 0 (0.0) |
| Polypharmacy only including prescription/OTC\(^1\) medicine | 743 (92.2) | 63 (7.8) |
| Polypharmacy including all types of medication (prescribed and non-prescription/OTC\(^1\) medicine, herbal and traditional medicine, dietary supplement) | 477 (59.2) | 329 (40.8) |

1: OTC: Over the counter.

https://doi.org/10.1371/journal.pone.0249849.t001
Studies from other countries have found the proportion of polypharmacy among people with diabetes range from 48% to 85% \[11,15,21,28–30\]. However, as definitions of polypharmacy vary, these data are not directly comparable. Thus, these studies defined polypharmacy as either prescription or OTC medicine \[11\], or only including prescribed medicine. When we

| Characteristic | Total (n = 806) | Polypharmacy\(^1\) | P-value |
|----------------|----------------|---------------------|---------|
|                | No (n = 477)   | Yes (n = 329)       |         |
| Sex            |                |                     |         |
| Men            | 381            | 228 (59.8)          | 153 (40.2) | 0.718 |
| Women          | 425            | 249 (58.6)          | 176 (41.4) |
| Age group (years) |             |                     |         |
| 40–54          | 92             | 63 (68.5)           | 29 (31.5) | 0.156 |
| 55–69          | 468            | 271 (57.9)          | 197 (42.1) |
| ≥70            | 246            | 143 (58.1)          | 103 (41.9) |
| Educational level |              |                     |         |
| Primary and below | 180           | 117 (65.0)          | 63 (35.0) | 0.131 |
| Middle school  | 500            | 292 (58.4)          | 208 (41.6) |
| College and above | 126           | 68 (54.0)           | 58 (46.0) |
| Marital status |                |                     |         |
| Married/living together | 593       | 354 (59.7)          | 239 (40.3) | 0.619 |
| Single/widowed/divorced | 213       | 123 (57.7)          | 90 (42.3) |
| Occupation (n = 798)\(^2\) |       |                     |         |
| Unemployed and stays at home | 140     | 82 (58.6)           | 58 (41.4) | 0.622 |
| Farmer         | 296            | 180 (60.8)          | 116 (39.2) |
| Small trade/worker/private company/government employee | 104     | 65 (62.5)           | 39 (37.5) |
| Retired        | 258            | 145 (56.2)          | 113 (43.8) |
| Economic status (self-reported) |           |                     |         |
| Poor/near poor | 95             | 52 (54.7)           | 43 (45.3) | 0.641 |
| Medium         | 638            | 381 (59.7)          | 257 (40.3) |
| Wealthy        | 73             | 44 (60.3)           | 29 (39.7) |
| Duration of diabetes (year) |          |                     |         |
| ≤1 year        | 152            | 106 (69.7)          | 46 (30.3) | 0.024 |
| >1–5 years     | 310            | 180 (58.1)          | 130 (41.9) |
| >5 years       | 344            | 191 (55.5)          | 153 (44.5) |
| Number of comorbidities |       |                     |         |
| 0              | 92             | 70 (76.1)           | 22 (23.9) | <0.001 |
| 1–2            | 446            | 267 (59.9)          | 179 (40.1) |
| ≥3            | 268            | 140 (52.2)          | 128 (47.8) |
| Diabetes-related distress\(^3\) |       |                     |         |
| No             | 403            | 256 (63.5)          | 147 (36.5) | 0.012 |
| Yes            | 403            | 221 (54.8)          | 182 (45.2) |
| Self-reported level of physical health |           |                     |         |
| Excellent/Good | 105            | 62 (59.0)           | 43 (41.0) | 0.99 |
| Fair           | 399            | 237 (59.4)          | 162 (40.6) |
| Poor/very poor | 302            | 178 (58.9)          | 124 (41.1) |

\(^1\) Polypharmacy: No: 0 to 4 medicines in use, Yes: ≥5 medicines in use.
\(^2\): 8 people had missing information about occupation.
\(^3\): Diabetes-related distress: Yes: Paid-5 score ≥ 8; No: Paid-5 score < 8.
This discrepancy may be partly explained by our study population: we included people with T2D who received treatment at a district hospital; in the Thai Binh, people with diabetes with more severe complications usually receive treatment at the provincial or national hospitals [31]. Moreover, most people with diabetes in Vietnam use health insurance to cover treatment and medicine for their disease and the insurance only covers the cost for a monthly check-up in district hospitals up to VND 223,500 (approximately 10 USD), including blood testing, medical examination fee, and medicine [32]. Thus, doctors may prescribe only the most important medicine/s to keep the cost within the limit.

When defining polypharmacy by including herbal and traditional medicine, the proportion of people with diabetes with polypharmacy was 40.8%, which suggests that people with substitute, supplement, or rely on non-pharmaceutical treatment for their diabetes. A study from Vietnam reported that reasons for this include people believing that a combination of conventional and herbal and traditional medicine will improve the effectiveness of their diabetes treatment [33]. A study conducted in the United States among Vietnamese immigrants showed that people with T2D even stop taking prescribed medicine when using traditional medicine because of worries of side effects of prescribed medicines [34]. Further, in Vietnam, using herbal and traditional medicine is considered a therapy with minimal or no side effect and entails lower financial costs [35,36]. This may be explained by traditional and herbal medicine having a long and honored history in Vietnam: for thousands of years, Vietnamese people have treated diseases with herbs and plants, which were gathered from gardens and forests. Thus, using traditional and herbal medicine is still an important component of national efforts to promote public health in urban and rural populations in Vietnam [37]. Nowadays, using traditional and herbal medicine are widely used beside Western medicine and traditional and herbal medicine are especially used when Western medicine is considered ineffective or too expensive [37].

In our study, longer duration of diabetes increased the ORs of polypharmacy. In studies conducted in China, Brazil and Italy among people with T2D showed that polypharmacy was

| Characteristic                  | Number of individuals with polypharmacya (%) | Results of bivariate analysis Crude odds ratio (95% CI) | Results of multivariate analysis Adjusted odds ratioa (95% CI) |
|--------------------------------|-----------------------------------------------|--------------------------------------------------------|-----------------------------------------------------------|
| Duration of diabetes (years)  |                                               |                                                         |                                                           |
| <1 year                        | 46 (30.2)                                     | 1                                                      | 1                                                         |
| >1–5 years                     | 130 (41.9)                                    | 1.66 (1.01–2.51)                                        | 1.66 (1.09–2.53)                                          |
| >5 years                       | 153 (44.5)                                    | 1.84 (1.23–2.77)                                        | 1.74 (1.14–2.64)                                          |
| Comorbidities                  |                                               |                                                         |                                                           |
| 0                              | 22 (23.9)                                     | 1                                                      | 1                                                         |
| 1–2                            | 179 (40.1)                                    | 2.13 (1.27–3.57)                                        | 2.01 (1.18–3.42)                                          |
| 3 or more                      | 128 (47.8)                                    | 2.90 (1.70–4.97)                                        | 2.63 (1.50–4.61)                                          |
| Diabetes-related distressb     |                                               |                                                         |                                                           |
| No                             | 147 (36.5)                                    | 1                                                      | 1                                                         |
| Yes                            | 182 (45.2)                                    | 1.43 (1.08–1.90)                                        | 1.49 (1.11–2.01)                                          |

1 Polypharmacy: No: 0 to 4 medicines in use, Yes: ≥5 medicines in use.
2 Distress: Yes: Paid-5 score ≥ 8; No: Paid-5 score <8.
CI: Confident interval.
* Adjusted for duration of diabetes, comorbidities, diabetes-related distress.

https://doi.org/10.1371/journal.pone.0249849.t003

defined polypharmacy including only prescribed medicines and OTC, only 7.8% had polypharmacy. This discrepancy may be partly explained by our study population: we included people with T2D who received treatment at a district hospital; in the Thai Binh, people with diabetes with more severe complications usually receive treatment at the provincial or national hospitals [31]. Moreover, most people with diabetes in Vietnam use health insurance to cover treatment and medicine for their disease and the insurance only covers the cost for a monthly check-up in district hospitals up to VND 223,500 (approximately 10 USD), including blood testing, medical examination fee, and medicine [32]. Thus, doctors may prescribe only the most important medicine/s to keep the cost within the limit.

When defining polypharmacy by including herbal and traditional medicine, the proportion of people with diabetes with polypharmacy was 40.8%, which suggests that people with substitute, supplement, or rely on non-pharmaceutical treatment for their diabetes. A study from Vietnam reported that reasons for this include people believing that a combination of conventional and herbal and traditional medicine will improve the effectiveness of their diabetes treatment [33]. A study conducted in the United States among Vietnamese immigrants showed that people with T2D even stop taking prescribed medicine when using traditional medicine because of worries of side effects of prescribed medicines [34]. Further, in Vietnam, using herbal and traditional medicine is considered a therapy with minimal or no side effect and entails lower financial costs [35,36]. This may be explained by traditional and herbal medicine having a long and honored history in Vietnam: for thousands of years, Vietnamese people have treated diseases with herbs and plants, which were gathered from gardens and forests. Thus, using traditional and herbal medicine is still an important component of national efforts to promote public health in urban and rural populations in Vietnam [37]. Nowadays, using traditional and herbal medicine are widely used beside Western medicine and traditional and herbal medicine are especially used when Western medicine is considered ineffective or too expensive [37].

In our study, longer duration of diabetes increased the ORs of polypharmacy. In studies conducted in China, Brazil and Italy among people with T2D showed that polypharmacy was
associated with duration of T2D of ≥5 years [15,21,38]. Other studies have also showed an association between diabetes duration and diabetes-related complications and comorbidities [39,40]. Longer duration is associated with increasing risk of diabetes complications and comorbidities [41], which may require additional medicine [42]. The requirement of additional medicine may also explain our results showing that the ORs of polypharmacy were associated with higher number of comorbidities, which is in line with recently published studies [15,21,43–45]. People with T2D are at high risk of arterial hypertension, cardiovascular disorder, hyperlipidemia, etc.,—all conditions, which require medicine: antihypertensive, antihyperlipidemic, antiplatelets medicines are often co-prescribed along with antidiabetic medicine [46].

We found that the OR of polypharmacy was higher among those with diabetes-related distress than those without diabetes-related distress. The results of studies showing that polypharmacy is associated with psychological distress in general [11,22]. People with less well-controlled diabetes may have higher distress due to the difficulties managing their disease and therefore try out different medicines in an effort to better control their disease [36]. On the other hand, polypharmacy may increase the risk of hospitalizations, morbidity and financial cost [47], which may increase the emotional and financial stress for people with diabetes, especially those living in rural Vietnam areas where the average monthly income is around 100 US$ [36,48].

**Limitations and strengths**

To our knowledge, this study is the first to report about polypharmacy in people with T2D in Vietnam. We collected data in rural and semi-urban areas and had a response-rate of 84%.

This study also has some limitations; selection bias may have occurred since we only included patients who had received treatment for T2D at district hospitals, which may have excluded 1) people who control their diabetes with diet and physical activity only, and are not in contact with a district hospital; and 2) people who receive diabetes treatment at regional hospital or provincial hospitals, which typically treat more severe cases of diabetes. These people would likely have lower or higher OR of polypharmacy, respectively, and we might have overestimated or underestimated the proportion of people with T2D with polypharmacy. Furthermore, non-responders constituted around 13.5% of the sample, which may have influenced the results: we did not systematically collect data about them, but they mostly reported being unavailable for interview due to being at work, and may thus have been younger and in better health, and have had a lower medicine use than the people included in the study. This study examined the association of polypharmacy including prescription/OTC medicines, herbal, traditional medicine and dietary supplement, the results could be different if the study was limited to only people using prescription/OTC medicines. Our study was conducted in Vietnam and the results cannot be generalized to other populations. Lastly, we do not know the types of medicine which people with T2D were taking and we cannot assess if they were over or undertreated.

**Conclusions**

Less than 10% of the study population reported a medicine intake corresponding to polypharmacy defined as prescription and non-prescription/OTC medicine, while the proportion increased to 41% when including herbal and traditional medicine and dietary supplements. Polypharmacy was more common among those persons with longer duration of T2D, higher number of comorbidities and diabetes-related distress. The study findings suggest that a high proportion of people with T2D supplement their treatment with herbal and traditional medicine and dietary supplements. Further research should focus on whether people with T2D in Vietnam are undertreated or overtreated, and if those with polypharmacy experience harmful effects.
Supporting information

S1 Table. Frequency of other disease among people with T2D.
(PDF)

S1 File. Questionnaire of study.
(PDF)

S2 File. Data of study.
(XLSX)

Acknowledgments

The present study is part of the interdisciplinary research project, Living Together with Chronic Disease: Informal Support for Diabetes Management in Vietnam (VALID) (17-M09-KU). This study is part of a collaborative project between ThaiBinh University of Medicine and Pharmacy and University of Copenhagen of Denmark. We are grateful to the staff at three district hospitals and village health workers from 8 communes in Thai Binh province. We also thank all the people from Quynh Phu and Vu Thu district who participated in the interview.

Author Contributions

Conceptualization: Dieu Huyen Thi Bui, Bai Xuan Nguyen, Dan Wolf Meyrowitsch, Jens Søndergaard, Ib Christian Bygbjerg, Nielsen Jannie.

Data curation: Dat Cong Truong, Nielsen Jannie.

Formal analysis: Dieu Huyen Thi Bui, Dat Cong Truong, Dan Wolf Meyrowitsch, Nielsen Jannie.

Funding acquisition: Bai Xuan Nguyen, Dan Wolf Meyrowitsch, Tine Gammeltoft, Ib Christian Bygbjerg.

Investigation: Dieu Huyen Thi Bui, Bai Xuan Nguyen, Tine Gammeltoft.

Methodology: Dieu Huyen Thi Bui, Dan Wolf Meyrowitsch, Ib Christian Bygbjerg, Nielsen Jannie.

Project administration: Bai Xuan Nguyen, Dan Wolf Meyrowitsch, Tine Gammeltoft.

Resources: Jens Søndergaard, Nielsen Jannie.

Software: Dat Cong Truong.

Supervision: Bai Xuan Nguyen, Dan Wolf Meyrowitsch, Tine Gammeltoft, Ib Christian Bygbjerg, Nielsen Jannie.

Validation: Tine Gammeltoft.

Visualization: Dieu Huyen Thi Bui, Dan Wolf Meyrowitsch, Jens Søndergaard, Ib Christian Bygbjerg.

Writing - original draft: Dieu Huyen Thi Bui.

Writing – review & editing: Dieu Huyen Thi Bui, Dan Wolf Meyrowitsch, Jens Søndergaard, Tine Gammeltoft, Ib Christian Bygbjerg, Nielsen Jannie.
References

1. Nguyen CT, Pham NM, Lee AH, Binns CW. Prevalence of and Risk Factors for Type 2 Diabetes Mellitus in Vietnam: A Systematic Review. Asia Pac J Public Health. 2015; 27(6):588–600. https://doi.org/10.1177/1010596X15595860 PMID: 26187848

2. International Diabetes Federation. Diabetes Atlas 7th edition. 2017.

3. Teljeur C, Smith SM, Paul G, Kelly A, O'Dowd T. Multimorbidity in a cohort of patients with type 2 diabetes. Eur J Gen Pract. 2013; 19(1):17–22. https://doi.org/10.3109/13814788.2012.714768 PMID: 23432037

4. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008; 359(15):1565–76. https://doi.org/10.1056/NEJMoa0806359 PMID: 18784091

5. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371(9607):117–25. https://doi.org/10.1016/S0140-6736(08)60104-X PMID: 18191683

6. Laakso M, Lehto S, Penttila I, Pyorala K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993; 88(4 Pt 1):1421–30. https://doi.org/10.1161/01.cir.88.4.1421 PMID: 8403288

7. Gonder-Frederick LA, Cox DJ, Ritterband LM. Diabetes and behavioral medicine: the second decade. J Consult Clin Psychol. 2002; 70(3):611–25. https://doi.org/10.1037/0022-006x.70.3.611 PMID: 12090372

8. World Health Organization. Global report on diabetes. 2016.

9. Maher RL, Hanlon JT, Hajjar ER. Clinical Consequences of Polypharmacy in Elderly. Expert Opin Drug Saf. 2014; 13(1). https://doi.org/10.1517/14740338.2013.827660 PMID: 24073682

10. Masnoon N, Shabik S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017; 17(1):230. https://doi.org/10.1186/s12877-017-0621-2 PMID: 29017448

11. Alwhaibi M, Bahlki B, Alhawassi TM, Alkoifide H, Alkofide N, Alabdulali R, et al. Polypharmacy among patients with diabetes: a cross-sectional retrospective study in a tertiary hospital in Saudi Arabia. BMJ Open. 2018; 8(5):e020852. https://doi.org/10.1136/bmjopen-2017-020852 PMID: 29794097

12. World Health Organization. Medication safety in Polypharmacy; 2019.

13. Byles JE, Heinze R, Nair BK, Parkinson L. Medication use among older Australian veterans and war widows. Intern Med J. 2003; 33(8):388–92. https://doi.org/10.1046/j.1445-5994.2003.00399.x PMID: 12895173

14. Thommanduru Priyanka AL, Alluru Revanth, Chakka Gopinath and Singanamalla Chandra Babu. Effect of Polypharmacy on Medication Adherence in Patients with Type 2 Diabetes Mellitus. Indian Journal of Pharmacy Practice. 2015; 8(3).

15. Silva M, Diniz LM, Santos J, Reis EA, Mata ARD, Araujo VE, et al. Drug utilization and factors associated with polypharmacy in individuals with diabetes mellitus in Minas Gerais, Brazil. Cien Saude Colet. 2018; 23(8):2565–74. https://doi.org/10.1590/1413-81232018238.10222016 PMID: 30137126

16. Nguyen TX, Nguyen TN, Nguyen AT, Nguyen HTT, Nguyen TN, et al. Polypharmacy at discharge in older hospitalised patients in Vietnam and its association with frailty. Australas J Ageing. 2019. https://doi.org/10.1111/ajag.12722 PMID: 31677221

17. Investment promotion center for North Vietnam [Internet]. 2018. Available from: http://ipcn.vn/en/regions/detail/135/thai-binh.html

18. Khue NT. Diabetes in Vietnam. Ann Glob Health. 2015; 81(6):870–3. https://doi.org/10.1016/j.aogh.2016.01.003 PMID: 27108154

19. Haider SI, Johnell K, Thorslund M, Fastbom J. Analysis of the association between polypharmacy and socioeconomic position among elderly aged ≥ 77 years in Sweden. Clin Ther. 2008; 30(2):419–27. https://doi.org/10.1016/j.clinthera.2008.02.010 PMID: 18343279

20. Geitona M, Latsou D, Toska A, Saridi M. Polypharmacy and Adherence Among Diabetic Patients in Greece. Consult Pharm. 2018; 33(10):562–71. https://doi.org/10.4140/TCP.n.2018.562. PMID: 30322433

21. Li J, Chattopadhyay K, Xu M, Chen Y, Hu F, Wang X, et al. Prevalence and predictors of polypharmacy prescription among type 2 diabetes patients at a tertiary care department in Ningbo, China: A retrospective database study. PLoS One. 2019; 14(7):e0220047. https://doi.org/10.1371/journal.pone.0220047 PMID: 31314797

22. Assari S, Bazargan M. Polypharmacy and Psychological Distress May Be Associated in African American Adults. Pharmacy (Basel, Switzerland). 2019; 7(1):14. https://doi.org/10.3390/pharmacy7010014 PMID: 30682807

23. McGuire BE, Morrison TG, Hermanns N, Skovlund S, Eldrup E, Gagliardino J, et al. Short-form measures of diabetes-related emotional distress: the Problem Areas in Diabetes Scale (PAID)-5 and PAID-1. Diabetologia. 2010; 53(1):66–3. https://doi.org/10.1007/s00125-009-1559-5 PMID: 19841892
24. Haider SI, Johnell K, Weitoff GR, Thorslund M, Fastbom J. The influence of educational level on polypharmacy and inappropriate drug use: a register-based study of more than 600,000 older people. J Am Geriatr Soc. 2009; 57(1):62–9. https://doi.org/10.1111/j.1532-5415.2008.02040.x PMID: 19054196

25. Josephine Valsa Jose PD, Satish Renuka. Polypharmacy and predictors of high level polypharmacy in patients with diabetic nephropathy in a tertiary care hospital. Medicine. 2019.

26. Wawruch M, Zikavska M, Wsolova L, Kuzelova M, Tisonova J, Gajdosik J, et al. Polypharmacy in elderly hospitalised patients in Slovakia. Pharmacy World & Science. 2008; 30(3):235–42. https://doi.org/10.1007/s11096-007-9166-3 PMID: 17943457

27. Bazargan M, Smith J, Saqib M, Helmi H, Assari S. Associations between Polypharmacy, Self-Rated Health, and Depression in African American Older Adults; Mediators and Moderators. International journal of environmental research and public health. 2019; 16(9):1574.

28. Rutters F, Oort Sv, Kramers K, Elders P. The characterisation of people with type 2 diabetes and polypharmacy in the Netherlands: the Diabetes Pearl cohort. Berlin The European Association for the Study of Diabetes; 2018.

29. Gadsby R, Galloway M, Barker P, Sinclair A. Prescribed medicines for elderly frail people with diabetes resident in nursing homes-issues of polypharmacy and medication costs. Diabet Med. 2012; 29(1):136–9. https://doi.org/10.1111/j.1464-5491.2011.03494.x PMID: 22004423

30. da Silva Corralo V, Marconatto Binotto V, Bohnen LC, Gonzaga Dos Santos GA, De-Sa CA. Polypharmacy and associated factors in elderly diabetic. Rev Salud Publica (Bogota). 2018; 20(3):366–72. https://doi.org/10.15446/rsap.v20n3.50304 PMID: 30844011

31. Nguyen T, Knight R, Mant A, Cao Q, Auton M. Medicine prices, availability, and affordability in Vietnam. Southern Med Review. 2009; 2:2–9. PMID: 23093870

32. Security VS. Direct payment of expenses of medical examination and treatment covered by medical insurance. 2019.

33. Kasole R, Martin HD, Kimiywe J. Traditional Medicine and Its Role in the Management of Diabetes Mellitus: “Patients’ and Herbalists’ Perspectives”. Evid Based Complement Alternat Med. 2019; 2019:2835691. https://doi.org/10.1155/2019/2835691 PMID: 31354852

34. Mull DS, Nguyen N, Mull JD. Vietnamese diabetic patients and their physicians: what ethnography can teach us. The Western journal of medicine. 2001; 175(5):307–11. https://doi.org/10.1136/ewjm.175.5.307 PMID: 11694472

35. Ung L, Lay H-L, Wu M-C. Herbs for the Management of Diabetes Mellitus in Traditional Vietnamese Medicine. Journal of Applied Biopharmaceutics and Pharmacokinetics. 2019; 7:1–7.

36. Dieu BTH. Non-using diabetic medication in health insurance–some reasons need special attention Vietnam Medical Journal. 2019; 48(3).

37. Loi DT, Duong NX. Native drugs of Vietnam: which traditional and scientific approaches? J Ethnopharmacol. 1991; 32(1–3):51–6. https://doi.org/10.1016/0378-8741(91)90103-k PMID: 1881167

38. Noale M, Verones e N, Cavallo Perin P, Pilotto A, Tiengo A, Ciglioni A, et al. Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment. Acta Diabetol. 2016; 53(2):323–30. https://doi.org/10.1007/s00592-015-0790-4 PMID: 26155958

39. Karlsen B, Oftedal B, Bru E. The relationship between clinical indicators, coping styles, perceived support and diabetes-related distress among adults with type 2 diabetes. J Adv Nurs. 2012; 68(2):391–401. https://doi.org/10.1111/j.1365-2648.2011.05751.x PMID: 21707728

40. Kasteleyn MJ, de Vries L, van Puffelen AL, Schellevens FG, Rijken M, Vos RC, et al. Diabetes-related distress over the course of illness: results from the DiaCourse study. Diabetic Medicine. 2015; 32(12):1617–24. https://doi.org/10.1111/dme.12743 PMID: 25763843

41. Knuiman MW, Welbom TA, McCann VJ, Stanton KG, Constable IJ. Prevalence of Diabetic Complications in Relation to Risk Factors. Diabetes. 1986; 35(12):1332–9. https://doi.org/10.2337/diab.35.12.1332 PMID: 3770311

42. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348(5):383–93. https://doi.org/10.1056/NEJMoa021778 PMID: 12556541

43. Horii T, Iwasawa M, Kabeya Y, Atuda K. Polypharmacy and oral antidiabetic treatment for type 2 diabetes characterised by drug class and patient characteristics: A Japanese database analysis. Sci Rep. 2019; 9(1):12992. https://doi.org/10.1038/s41598-019-49424-2 PMID: 31506542

44. Austin RP. Polypharmacy as a Risk Factor in the Treatment of Type 2 Diabetes. Diabetes Spectrum. 2006; 19(1):13–6.

45. Dobrica EC, Gaman MA, Cozma MA, Bratu OG, Pantea Stoian A, Diaconu CC. Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department. Medicina (Kaunas). 2019; 55(8). https://doi.org/10.3390/medicina55080436 PMID: 31382651
46. Indu R, Adhikari A, Maisnam I, Basak P, Sur T, Das A. Polypharmacy and comorbidity status in the treatment of type 2 diabetic patients attending a tertiary care hospital: An observational and questionnaire-based study. Perspectives in Clinical Research. 2018; 9(3):139–44. https://doi.org/10.4103/picr.PICR_81_17 PMID: 30090713

47. Wimmer BC, Bell JS, Fastbom J, Wiese MD, Johnell K. Medication Regimen Complexity and Number of Medications as Factors Associated With Unplanned Hospitalizations in Older People: A Population-based Cohort Study. The Journals of Gerontology: Series A. 2015; 71(6):831–7. https://doi.org/10.1093/gerona/glv219 PMID: 26707381

48. Vietnam Monthly Income per capita: Rural [Internet]. 2017. Available from: https://www.ceicdata.com/en/vietnam/monthly-income-per-capita/monthly-income-per-capita-rural.